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Abstract: Combined oral contraceptive pills (cOCPs) are often used in the treatment of acne 
in females. They are effective, safe, and easy to use in appropriate patients in combination with 
more conventional acne therapies. This article will briefly address the physiologic rationale for 
the use of cOCPs in the treatment of acne. It will also review efficacy by examining relevant 
clinical trials. Safety considerations and the adverse event profile for oral contraceptives will be 
presented. Finally, practical considerations for prescribing cOCPs will be discussed.
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Introduction
Acne is a problem for women in all age groups. It generally begins at adrenarche, 
between the ages of 8 and 10 years, and peaks around age 17. Studies have shown that 
100% of females are affected sometime during their adolescent years.1 While often 
considered a side effect of puberty, adult acne is also fairly common, occurring in 5% 
to 12% of adult women. Surprisingly, it can continue to be a problem for some women 
even into their postmenopausal years.
The psychosocial impact of acne is undeniable; adversely impacting the quality of 
life of those affected. Studies have shown that the level of impairment is similar to that 
seen in arthritis, back pain, diabetes, asthma, and epilepsy.2 Adults with severe acne 
have decreased employment rates compared to their unaffected peers.3 In addition to 
the psychological toll, acne can lead to permanent scarring and result in significant, 
life-long disfigurement.
Therefore, effective use of all available acne treatments is paramount to gaining 
control of this disorder and helping those affected. While excellent treatments are avail-
able, acne in females can pose a unique challenge for the treating physician. It is often 
recalcitrant to conventional acne therapies, including systemic antibiotics and even 
isotretinoin. Combined oral contraceptives and other hormonally targeted treatments 
can be effective in this group of patients and should be considered in the treatment 
plan for females with acne. Their use will be reviewed in this article.
Physiology/basic science rationale
Acne physiology
Four major processes are felt to play a role in the pathogenesis of acne: 1) Follicular 
hyperkeratinization contributes to the formation of a primary acne lesion, the comedone. 
This hyperkeratinization causes follicular plugging which then entraps the follicles International Journal of Women’s Health 2010:2 70
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contents, including sebum and bacteria. 2) Increased sebum 
production results in extension of the follicular unit and 
assists with plug formation. 3) Comedone rupture initiates an 
inflammatory cascade in the surrounding tissues resulting in 
the recruitment of immune cells and the formation of inflam-
matory papules, pustules and nodules. 4) Propionibacterium 
acnes, bacteria present on the skin surface and within fol-
licular units, thrives in this environment, and contributes to 
the inflammatory cascade through its activation of toll-like 
receptor 2 (TLR2) and other mediators.4
Different acne treatments target these different, yet 
entwined processes. For instance, benzoyl peroxide is 
bactericidal against P. acnes. Salicylic acid and topical 
retinoids are comedolytic and decrease follicular hyperke-
ratinization. Topical retinoids also decrease TLR-2 expres-
sion.5 Antibiotics play both an anti-inflammatory role and 
are bactiostatic against P. acnes. Hormonal therapies, like 
combined oral contraceptive pills (cOCPs), target sebum 
production and may also play a role in decreasing follicular 
hyperkeratinization.6–8 Oral isotretinoin is the only medica-
tion that exerts action against all four of the steps, but its 
mechanism of action has not been fully elucidated.
Sebum production is upregulated during physiologic 
and pathologic states of increased androgen production 
and acne is seen in these conditions. In women, andro-
gens are produced primarily by the ovaries and adrenal 
glands. Acne typically begins during adrenarche, when 
the adrenal gland begins to produce large quantities of 
dehydroepiandrosterone (DHEAS). Acne also develops in 
conditions of androgen excess; including polycystic ovar-
ian syndrome, adrenal and ovarian tumors, and congenital 
adrenal hyperplasia. Administration of testosterone, dehy-
droepiandrosterone, and androstenedione have been shown 
to increase sebum production and the size of sebaceous 
glands.9,10 Acne flares are also seen during periods of stress, 
which is also a state of increased adrenal androgens. Inter-
estingly, castrated male patients, those without testicular 
androgens, and those with androgen receptor defects are 
not afflicted with acne.11
Most females with acne will have circulating androgen 
levels within the normal range. However, studies have shown 
that as a group, females with acne trend towards the higher 
end of normal.12 It may also be that androgen metabolism is 
increased at the level of the pilosebaceous unit as well, either 
independently or dependently on the level of circulating 
androgens. Androgen receptors have been localized to the 
outer root sheath of keratinocytes and to the basal layer of 
the sebaceous gland.13,14 Androgens are thought to stimulate 
growth and differentiation of sebaceous glands. The exact 
molecular mechanisms are yet to be elucidated.
How do oral contraceptives work?
cOCPs include an estrogen component, usually ethinyl 
estradiol, and a progestin component which will vary. 
Estrogens are known to decrease sebum production. They 
are hypothesized to accomplish this in several ways, both 
locally at the level of the sebaceous gland, and systemi-
cally.15 First, they may directly oppose androgens at the 
local level and regulate genes involved in sebum production 
and sebaceous gland growth.15 Second, they provide nega-
tive feedback on the pituitary/hypothalamus. That is, they 
inhibit the anterior pituitary’s production of luteinizing hor-
mone (LH) and follicle-stimulating hormone (FSH), thus 
decreasing ovarian production of the androgen, testosterone. 
Third, estrogen administration increases sex hormone bind-
ing globulin, which binds serum testosterone, decreasing 
the amount of free testosterone available to bind with the 
androgen receptor.15 The efficacy of cOCPs in the treatment 
of acne is felt to be secondary to these estrogenic effects. 
Ethinyl estradiol is the estrogen in most oral contraceptives 
and comes in various dosages and dosing regimens. First-
generation oral contraceptives had higher doses of ethinyl 
estradiol, around 0.1 mg. Newer formulations contain much 
lower doses of estrogen, typically 0.020 to 0.035 mg, which 
minimize the adverse effects that can be associated with 
estrogen use. These lower dose estrogens still maintain the 
ability to suppress sebum production.
Use of estrogen has several safety issues, including: 
increased cardiovascular disease and hypercoagulability, 
and an increased risk of endometrial and breast cancers. To 
minimize the risk, most cOCPs include a combination of an 
estrogen with a progestin. Synthetic progestins act at the pro-
gesterone receptor but also react with the androgen receptor 
to varying degrees and thus may potentiate acne. They can 
also cause glucose intolerance and interfere with the effect of 
estrogen on sex-hormone binding globulin. Older synthetic 
progestins like the first-generation gonane, norethindrone, and 
the second-generation estranges, norgestrel and levonorgestrel, 
were derived from progesterone. In vitro studies suggest that 
these progestins may cross-react with the androgen receptor.16 
Newer synthetic progestins, like the third-generation gonanes, 
desogestrel and norgestimate, have less activity at the 
androgen receptor and more specificity for the progestin recep-
tor, thus the androgenic effects are minimized. Drosperinone 
is a relatively new fourth-generation progestin with a pharma-
cologic profile that is more similar to progesterone. It blocks International Journal of Women’s Health 2010:2 71
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endogenous androgens from binding the androgen receptor 
and is thus anti-androgenic. Drosperinone is an analogue 
of spironolactone, a diuretic with anti-mineralocorticoid   
activity and anti-androgen activity also used in the treatment 
of acne. Drosperinone’s anti-mineralocorticoid properties may 
help to counteract the bloating and water retention produced 
by estrogen in the cOCPs. Multiphasic cOCPs with varying 
progestin levels were designed to minimize androgenic effects 
by decreasing the overall amount of progestin delivered over 
the course of the cycle. They start with lower progestin levels 
and increase to provide the higher androgen dose at the end of 
the menstrual cycle, which more closely mimics physiology.17 
Fortunately, in all cOCPs, the effects of the estrogen outweigh 
the effects of the progestin and therefore the overall effect is a 
decrease in androgen levels and improvement in acne.
Efficacy
Clinical trials have shown that cOCPs are effective in the 
treatment of acne. Changes in lesion counts, physician 
global assessments, and patient satisfaction have gener-
ally been the outcome measures of these studies. Though 
many cOCPs have shown efficacy in the treatment of acne 
in clinical trials, and all are hypothesized to work through 
their estrogenic effects, only 3 oral contraceptives have 
been approved by the FDA in the United States for use in 
patients with acne who desire contraception. These include: 
norgestimate 0.180 mg/0.215 mg/0.25 mg ethinyl estra-
diol 0.035 mg (Ortho-TriCyclen®; Ortho-McNeil-Janssen 
  Pharmaceuticals, Inc.), norethindrone 1 mg ethinyl estradiol 
0.020 mg/0.030 mg/0.035 mg (Estrostep®; Warner Chilcott), 
and drospirenone 3 mg ethinyl estradiol 0.02 mg (YAZ®; 
Bayer HealthCare). Cyproterone acetate (Diane®, Dianette®) 
is a synthetic derivative of 17-hydroxyprogesterone, approved 
in Europe for the treatment of acne, hirsutism and alopecia, 
but is not available in the United States. It may be used as 
a sole agent or in combination with ethinyl estadiol. While 
few are approved for the use in acne, clinical trials suggest 
that many other oral contraceptives are also effective. Those 
with ethinyl estradiol and levonorgestrel, desogesterel, norg-
estimate, gestodene, norethindrone acetate, chlormadinone 
acetate, drospirenone, cyproterone acetate, all have demon-
strated efficacy in the treatment of acne.
A recent Cochrane review provided a comprehensive 
assessment of the efficacy of cOCPs for the treatment of 
acne in women.18 This review looked at all randomized 
controlled clinical trials which compared any combined 
cOCP to either a second cOCP, oral antibiotic, topical 
acne treatment, no treatment or placebo. Included studies 
were required to assess at least one of the following 
measurements: change in specific lesion types, change in 
total lesion counts, physician or patient global assessment, 
psychosocial function outcome, and early discontinuation 
secondary to adverse events, including worsening of acne. 
A total of 81 trials were identified with 23 trials (a total 
of 7162 patients) meeting inclusion criteria. Metanalysis 
revealed the following conclusions: cOCPs reduced inflam-
matory and non-inflammatory lesion counts, resulted in 
decreased acne severity grades, and improved patients’ 
self assessment of acne in all of the trials comparing oral 
contraceptives to placebo. In most of the studies analyzed, 
total acne lesion counts decreased 40% to 60% with cOCP 
use, while an approximate 30% reduction in total lesion 
counts was seen in placebo groups. Typically, inflam-
matory lesion counts show greater improvement than 
noninflammatory lesion counts. Studies comparing oral 
contraceptives did not convincingly show superiority of 
one oral contraceptive to another in the treatment of acne. 
cOCPs containing chlormadinone acetate or cyproterone 
acetate seemed to improve acne better than those containing 
levonorgestrel; however, this was based on limited clinical 
data. Discontinuation secondary to adverse events also did 
not vary between cOCPs. There were not enough trials to 
reach a conclusion about cOCPs versus oral antibiotics. 
Nor were there head to head studies comparing topical 
acne treatments with cOCPs deemed adequate enough to 
include in the review. Compilation of evidence was difficult 
due to variable study designs. More research needs to be 
done to draw conclusions about the comparative efficacy 
of different cOCPs.
Safety
There are several important safety concerns and interactions 
to consider when starting a patient on oral contraceptives. 
More serious adverse events may occur in certain patients 
and should thus be avoided in those at risk (Table 1). All 
patients starting on cOCPs for acne should be thoroughly 
vetted regarding risk factors, with particular focus on lifestyle 
choices and family history. Patients should be routinely coun-
seled about possible side effects from cOCP use and asked 
about the development of any side effects at their follow-up 
appointments.
Hormonal changes lead to the most common side effects. 
Nausea, breast tenderness, headache, and bloating are 
attributed to the estrogen component of the cOCP. Fatigue, 
irritability, weight gain, acne, oily skin, increased low-density 
lipoprotein level (LDL) and breast tenderness are attributed International Journal of Women’s Health 2010:2 72
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to the progestin component of the cOCP. Decreased libido 
is also attributed to low progesterone levels.
Menstrual irregularity can also occur. As the levels of 
estrogen in cOCPs has decreased, the incidence of unsched-
uled bleeding and spotting has increased. If estrogen levels 
are too low, hypomenorrhea and early cycle breakthrough 
bleeding can occur. If progesterone levels are low, late cycle 
breakthrough bleeding results. Knowledge of these effects can 
help the clinician choose the right cOCP for their patient and 
troubleshoot any problems with ongoing cOCP therapy.
cOCPs now carry a black box warning regarding their risk 
of cardiovascular events, including venous thromboembolism 
(VTE). The greatest risk for VTE occurs within the first year of 
use and among carriers of thrombogenic mutations.19 The WHO 
Medical Eligibility Criteria for Contraceptive Use advises that 
the risks of cOCP use may outweigh the benefits in women with 
known thrombophilias.20 Examples of such thrombophilias 
include: factor V Leiden deficiency, protein C and protein S 
deficiencies, antithrombin III deficiency, dysfibrinogenemia, 
prothrombin 20210, hyperhomocysteinemia, resistance to 
activated protein C, and high levels of factor VII and von 
Willebrand factor. Women with factor V Leiden deficiency 
who use cOCPs have a 35-fold increase risk of developing 
VTE over their baseline risk. Depending on whether they are 
heterozygous or homozygous, the increase in risk ranges from 
4- to 10-fold, to 50- to 100-fold, respectively.21 Other factors 
that increase risk for VTE in women taking cOCPs include: 
age greater than 45, smoking greater than 10 cigarettes per 
day, and personal history of VTE.22–24 A personal and family 
history query to evaluate risk factors for VTE and cardio-
vascular disease and baseline blood pressure and body mass 
index should be performed prior to starting cOCPs. Although a 
serious potential side effect, the incidence of VTE is rare, and 
routine screening of asymptomatic women without a family 
history of thrombophilia is not recommended.25
Both the amount of estrogen and type of progestin play 
a role in VTE. There is reduced risk with lower amounts 
of ethinyl estradiol.26 Recently, there has been concern that 
certain progestins may increase this risk. Drospirenone and 
cyproterone, which both have antiandrogen activity, have 
been suggested to carry a greater risk of VTE.27,28 While there 
have been no randomized controlled trials, case control stud-
ies and a cohort analysis suggest that cyproterone may carry 
up to a four-fold increased risk.29,30 However, the European 
Active Surveillance, a large prospective, controlled, multina-
tional cohort study of new users of drosperinone, and other 
progestin containing oral contraceptives, reported similar 
rates and identical hazard ratios for venous thromboembolism 
in users of drospirenone containing cOCPs versus others.31
Users of cOCPs do carry a risk of developing hypertension; 
therefore blood pressure should also be monitored during 
follow-up visits. Other cardiovascular events that have evidence 
for association/risk include: arterial thromboembolism, cere-
bral hemorrhage and thrombosis, mesenteric thrombosis, and 
myocardial infarction. There is also evidence for associa-
tion/risk for the development of gallbladder disease, hepatic 
adenomas and other benign liver tumors, and retinal thrombo-
sis in patients taking cOCPs. There are many other reactions 
that patients may experience that are considered related to 
the use of cOCPs. Leg edema and varicose vein aggravation 
are additional cardiovascular risks. Neurologic side effects 
include: depression, migraine, mood changes, and worsening 
chorea. Dermatologic effects include chloasma, melasma, and 
other rare dermatoses. Nausea, vomiting, abdominal pain and 
cramping, appetite changes, bloating, cholestatic jaundice, 
and focal nodular hyperplasia are additional gastrointestinal 
and hepatic adverse events. Genitourinary side effects 
include: cervical ectropion, cervical secretions, enodcervical 
hyperplasia, fibroid enlargement, vaginal candidiasis and 
vaginitis. cOCP use may cause exacerbation of porphyria, 
and decrease folate levels. Rhinitis might also occur with 
their use. Ophthalmologic side effects include contact lens 
intolerance, and change in corneal curvature. Anaphylactic 
and anaphylactoid reactions may also occur.
Table 1 Contraindications to oral contraceptive use  
Smokers greater than 35 years old Morbid obesity
Undiagnosed abnormal  
uterine bleeding
estrogen dependent neoplasms, breast cancer, endometrial cancer, hepatic  
adenomas and carcinomas
Pregnancy and lactation History of jaundice in pregnancy or with prior OCP use
Thromboembolic disease Hypersensitivity
Hypercoagulable  
states
Migraine headaches after age 35 or before age 35 with focal neurologic  
deficits/aura
Cardiovascular disease including poorly controlled hypertension,  
angina, complicated valvular disease
Diabetes with evidence of nephropathy, retinopathy, neuropathy, vascular  
disease or 20 years duration
Hypertriglyceridemia Severe cirrhosisInternational Journal of Women’s Health 2010:2 73
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Use of cOCPs containing the progestin, drosperinone, 
may also result in an increase in serum potassium levels. 
Monitoring of potassium levels should be done in patients 
with underlying kidney disease, or those taking medications 
that can increase serum potassium levels, such as nonsteroidal 
anti-inflammatory agents, angiotensin-converting enzyme 
inhibitors, angiotensin II receptor antagonists, aldosterone 
anatagonists, and heparin. Also, acne patients treated with 
spironolactone in combination with a drosperinone con-
taining cOCP should be closely monitored for excessive 
potassium levels.
Oral contraceptives and oral tetracyclines are commonly 
used together in the treatment of acne. Backup contracep-
tion for patients using these medications concomitantly is 
routinely recommended by pharmacists. The mechanism 
of interference may be due to an alteration of the bacte-
rial flora resulting in the impaired absorption of estrogens. 
However, in patients taking doxycycline and tetracycline, 
studies have shown that estrogen levels are unaffected.32,33 
While there have been case reports of pregnancy occurring 
on such combinations, pregnancy rates were no greater than 
those from failure rates reported from the cOCP alone.34,35 
Individual variations in estrogen metabolism likely explain 
oral contraceptive failure.36 However, what additional impact 
the use of oral antibiotics has on those individuals needs to 
be further studied. Currently, there are no pharmacokinetic 
data or randomized controlled clinical trials supporting that 
oral antibiotics decrease the efficacy of oral contraceptives, 
with the notable exception of anti-tuberculosis drugs like 
rifampin.32
If the onset of acne in females is acute and severe, or 
if the acne is accompanied by signs of hyperandrogenism, 
investigations should be performed to rule out an underlying 
endocrine abnormality. A complete medical history and 
physical examination should be performed in these patients 
looking for signs of hyperandrogenism. These signs include: 
irregular menstrual periods, obesity, hypertrichosis, female 
pattern alopecia, clitoromegaly, and deepening of the voice. 
An appropriate minimum laboratory workup includes draw-
ing serum total testosterone, free testosterone, and DHEAS. 
Some also advocate drawing LH and FSH. These should be 
performed during the luteal phase of the menstrual cycle 
and women should be off oral contraceptives for at least 
one month prior. If DHEAS is elevated, the adrenal gland is 
the source of the excess androgens. DHEAS levels greater 
than 8000 ng/dL are indicative of a possible adrenal tumor. 
DHEAS levels between 4000 and 8000 ng/dL may indicate 
the presence of congenital adrenal hyperplasia. If testosterone 
levels are elevated, while DHEAS levels remain normal, 
the ovaries are the source of excess androgens. If the total 
testosterone is greater than 150 to 200 ng/dL an ovarian tumor 
may be the source. Mild elevations in total testosterone may 
be indicative of polycystic ovarian syndrome. An increased 
ratio of LH to FSH is also indicative of this. Patients identified 
with abnormalities should be appropriately referred to 
specialists.
Another question that practitioners often ask when start-
ing oral contraceptives is when to initiate Papanicolaou 
smear screening for cervical cancer prevention, especially in 
adolescents. The current recommendation of the American 
College of Obstetricians and Gynecologists written in 2003 
is as follows: cervical cancer screening should begin within 
3 years after first vaginal intercourse or by age 21, whichever 
comes first. Guidelines for subsequent screening vary based 
on age, type of screening test, and prior test results. Physicians 
prescribing oral contraceptives should routinely ask their 
Table 2 Starting oral contraceptives
  First day start Sunday start Quick start
When to take 1st pill Started on first day of menses Started on the first Sunday after  
the onset of menses
Started anytime during the  
menstrual cycle after a negative  
urine pregnancy test
Back-up contraception Back-up contraception not needed  
but advocated by some for the  
first week
If Sunday falls on days 1–5 of menses:  
back-up contraception advocated for the  
first week  
If Sunday falls on days 6–7 of menses: back-up  
contraception needed for the first month
Back-up contraception needed  
for the first month
Advantages Less chance of pregnancy  
occurring during first month
easier pill administration- most  
packets of pills labeled with day of the week
Better patient compliance
Disadvantages 
 
Poorer patient compliance 
 
Poorer patient compliance 
 
Possibility of pregnancy occurring 
during first month, despite  
negative initial testingInternational Journal of Women’s Health 2010:2 74
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patients about their sexual activity and refer their patients to 
a gynecologist or primary care provider when appropriate.
Practical management tips
How to start oral contraceptives
cOCPs may be started in three different ways (Table 2). 
They may be started on the first day of the patient’s men-
strual period, within 24 hours of the period commencing. 
This is known as “First Day Start” method. The theoretical 
advantage to this method is that there is no need for backup 
contraception. Despite this, however, many practitioners 
still instruct their patients to use backup contraception for 
the first week.
In the “Sunday Start” method, the first pill is taken on the 
Sunday following the first day of the last menstrual period. 
Backup contraception should be used for the first week if it 
is started between days 1 and 5 of menses. If Sunday falls 
beyond day 5, backup contraception should be used for the 
entire first month.
In the “Quick Start” method, cOCPs may be started at 
any time during the menstrual cycle. This has been shown to 
increase compliance. In this method, a urine pregnancy test 
is drawn in the office and, if negative, the patient may begin 
taking the cOCPs immediately. Some practitioners have their 
patients take their first pill in the office to increase compli-
ance.37 Patients should use a backup form of contraception 
for the first month when using the “Quick Start” method. Fear 
of undiagnosed pregnancy is a barrier to physician prescrip-
tion of cOCPs. Physicians may delay pill initiation until the 
patient’s next period if they have engaged in unprotected 
intercourse, in fear of teratogenicity. Although cOCPs carry a 
pregnancy category rating X, according to current literature, 
exposure to oral contraceptives during early pregnancy is 
not teratogenic or dangerous to pregnancy.38,39 There is no 
association between genital and nongenital malformations 
and the use of low dose oral contraceptives during early 
pregnancy.40–42 If pregnancy does occur in a patient using 
the “Quick Start” method, the pregnancy is easily diagnosed 
after the patient does not experience withdrawal bleeding 
during the placebo cycle of her oral contraceptive pack.43,44 
The use of cOCPS in pregnancy for the treatment of acne is 
obviously contraindicated.
Spotting/breakthrough bleeding  
and how to manage
Spotting and breakthrough bleeding may be a problem for 
women started on oral contraceptives. Spotting is defined as 
bleeding not requiring sanitary protection while breakthrough 
bleeding requires the use of a tampon or menstrual pad. Up 
to 20% of women stop using oral contraceptives secondary 
to this side effect.45 Spotting and breakthrough bleeding 
are common in the first 3 to 4 months after starting oral 
contraceptives and patients should be counseled regarding 
this side effect. After this period, it tends to cease. Both the 
amount of estrogen and progestin and the type of progestin 
can contribute to breakthrough bleeding. Estrogen causes 
uterine lining proliferation and progesterone stabilizes the 
uterine lining. Too little estrogen or too little progesterone 
can lead to spotting and breakthrough bleeding. Early cycle 
bleeding is thought to be secondary to low estrogen and late 
cycle bleeding to low progesterone. cOCPs with the same 
amount of estrogen, but different types of progestins, also 
have significant differences in spotting and breakthrough 
bleeding.46 The choice of progestin is thus important. The 
estrogen to progesterone ratio is also important. In studies 
where the ratio of estrogen to progesterone was maintained 
but the concentrations varied, preservation of the ratio 
was associated with acceptable levels of breakthrough 
bleeding.47
cOCPs are available as monophasic, biphasic, triphasic, 
extended cycle, and continuous use preparations. Extended 
cycle and continuous use preparations, which allow for less 
withdrawl bleeds, have the highest incidence of breakthrough 
bleeding. Biphasic and triphasic cOCPs were designed to 
lower the amount of hormones in cOCPs without increas-
ing the incidence of breakthrough bleeding, and possibly 
decrease this incidence, though evidence has been insufficient 
to support this.48
Other factors that may contribute to breakthrough 
bleeding include: lack of adherence, smoking, and medica-
tion interactions. For example, skipping a pill or failing to 
take a pill at the same time each day can lead to spotting. 
In patients who smoke, the habit decreases the estrogenic 
effectiveness of the pill. This is felt to be secondary to the 
induction of hepatic estrogen and also progesterone metabo-
lism by cigarette smoking.49,50 Smokers have higher rates of 
menstrual irregularities and more breakthrough bleeding.51 
Also, certain prescription and OTC medications, particularly 
those that induce the cytochrome P450 system, can cause 
breakthrough bleeding and can cause contraceptive failure. 
Examples of common P450 inducers include: rifampin, 
isoniazid, dexamethasone, griseofulvin, anticonvulsants and 
alcohol, though the list is more extensive. Pathologic causes 
of intermenstrual bleeding may mimic breakthrough bleeding 
and spotting and should be ruled out. For example, uterine or International Journal of Women’s Health 2010:2 75
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cervical malignancy and cervicitis from sexually transmitted 
diseases may cause bleeding between menstrual periods. If 
bleeding extends beyond 4 months, or begins after a patient 
has been on a cOCPs for several months without bleeding, 
an investigation is warranted.52
Strategies for managing breakthrough bleeding are as 
follows and summarized in Table 3. First, rule out lack of 
adherence, smoking, and medication effects by taking a good 
history. Pathologic processes, as noted above, that may be 
causing unexpected bleeding should be considered. Next, it 
should be determined when during the cycle the breakthrough 
bleeding or spotting occurs. If it is early in the cycle, supple-
mentation with estrogen may be helpful. Estrogen 1.25 mg/day 
or estradiol 2 mg/day may be given for 7 days when bleed-
ing occurs.52 This may be repeated if necessary. However, 
changing the oral contraceptive to one with a greater amount 
of ethinyl estradiol may also help and be a more permanent 
solution. This may be particularly helpful for women tak-
ing cOCPs with low doses of ethinyl estradiol (35 µg). If 
breakthrough bleeding occurs late in the cycle, changing the 
oral contraceptive to one with a higher concentration, or more 
androgenic type of progestin, may be beneficial. Switching 
from a multiphasic to a monophasic pill may also solve the 
problem as it allows for a steady dosing of progestin. Of 
utmost importance is managing patient’s expectations up front 
by educating patients about this potential side effect.
Conclusion
Several combined oral contraceptive preparations have 
proven to be effective and safe in the treatment for acne in 
women when used appropriately. All of those approved for 
use in acne, and many others, have near equal efficacy in 
decreasing total acne lesion counts, with a greater effect on 
inflammatory acne. Their use should regularly be considered 
in female patients with acne, especially those not responding 
to first line treatments, namely topical therapies and oral 
antibiotics. Careful screening and selection of patients is 
important to minimize risk. Understanding relevant safety 
concerns with a focus on patient risk factors, including 
hypertension, smoking and thrombophilias, will help mini-
mize adverse events. In addition, a working knowledge of the 
individual combined oral contraceptive formulations can help 
the prescriber to select the best medication for their patient 
and help with troubleshooting when problems arise. With this 
knowledge, any physician who regularly treats acne can safely 
include cOCPs in their therapeutic armamentarium.
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